Patents
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
03/2004
03/18/2004WO2003029280A3 Grb7: novel regulator of lymphocyte signaling
03/18/2004WO2003029279A3 Immunodominant acetylcholine receptor alpha subunit peptide: mhc complexes
03/18/2004WO2003028630A3 Methods and compositions for modulating interleukin-21 receptor activity
03/18/2004WO2003022202A3 Compositions and methods for treatment of cancer
03/18/2004WO2003014308A3 Cysteine mutants and methods for detecting ligand binding to biological molecules
03/18/2004WO2003013228A3 Biochemistry-related polynucleotides and polypeptides in plants
03/18/2004WO2003007800A8 Methods for diagnosing and treating diseases and conditions of the digestive system and cancer
03/18/2004WO2003006641A3 Epsti1, a gene induced by epithelial-stromal interaction in human breast cancer
03/18/2004WO2002103024A3 Stabilized proteins with engineered disulfide bonds
03/18/2004WO2002102982A3 Hoxd3 compositions ad methods for improved wound healing
03/18/2004WO2002102970A3 Flax (linum usitatissimim l.) seed-specific promoters
03/18/2004WO2002098454A3 Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
03/18/2004WO2002096938A3 Human kunitz-type protease inhibitor
03/18/2004WO2002092020A3 Compositions and methods for modulating bone mineral deposition
03/18/2004WO2002090567A9 Sperm-specific cation channel, and uses therefor
03/18/2004WO2002078516A3 Compositions and methods for the therapy and diagnosis of cancer
03/18/2004WO2002077195A3 Plasmodium falciparum ama-1 protein and uses thereof
03/18/2004WO2002072768A3 ISOGENIC ss-CATENIN CELL LINES, AND METHODS OF MAKING AND USING SAME
03/18/2004WO2002063009A3 Lp mammalian proteins; related reagents
03/18/2004WO2002059268A3 Factor ixa: factor viiia interaction and methods therefor
03/18/2004WO2002055694A3 Discriminative nucleic acid analysis using clone sequence signatures
03/18/2004US20040055040 Genetically modified plants and plant cells comprising heterologous heavy metal transport and complexation proteins
03/18/2004US20040055039 Expression vector coding regulatory sequence for transcription of heterologous nucleotide sequences in fruit of plants; tissue engineering
03/18/2004US20040055038 Methods and compositions for regulated transcription and expression of heterologous genes
03/18/2004US20040055036 Toxin genes from the bacteria xenorhabdus nematophilus and photorhabdus luminescens
03/18/2004US20040055032 Pyrophosphatase stress-related proteins and methods of use in plants
03/18/2004US20040055027 Producing food products from a transgenic non-human animal with increased number of ribs; treating obesity, spinal cord injury, kidney, nervous system and muscular diseases; antisense agents
03/18/2004US20040055026 Neurological disease model
03/18/2004US20040055024 Conditional mutants of influenza virus M2 protein
03/18/2004US20040055023 Animal models which concurrently expresses insulin and glucokinase gene in muscle cells; treating pancreatic disorders
03/18/2004US20040055022 Compositions and methods for screening therapeutic agents
03/18/2004US20040054480 Three dimensional structures and models of Fc receptors and uses thereof
03/18/2004US20040054165 Bacterial polysaccharide and biofilm development
03/18/2004US20040054159 Use of parapox b2l protein to modify immune responses to administered antigens
03/18/2004US20040054158 GL50 molecules and uses therefor
03/18/2004US20040054156 Method and reagent for inhibiting hepatitis B viral replication
03/18/2004US20040054147 Novel protein, its gene, reagents for inducing apoptosis, and anticancer agent
03/18/2004US20040054146 Allergy vaccines
03/18/2004US20040054145 Truncated cd200
03/18/2004US20040054143 Vegf peptides and their use for inhibiting angiogenesis
03/18/2004US20040054142 Cripto tumour polypeptide
03/18/2004US20040054141 Proton-translocating retinal protein
03/18/2004US20040054140 Neuronal differentiation regulating factor for treatment of central nervous system disorders
03/18/2004US20040054139 Chimeric genetically engineered DNA viral protein for use in immunotherapy and vaccine development
03/18/2004US20040054137 Chimeric protein for diagnosis and treatment of cancers and infections; immunotherapy
03/18/2004US20040054136 Comprises nucleotide sequences coding transporter associated with antigen processing-like polypeptides (human TAP-like) for diagnosis and treatment of infection, tumors and autoimmune diseases
03/18/2004US20040054135 Calcineurin polypeptide for diagnosis and treatment of cardiovascular disorders
03/18/2004US20040054134 Hcv ns2/3 fragments and uses thereof
03/18/2004US20040054133 Multiple sclerosis-related superantigen
03/18/2004US20040054132 Comprises fatty acid-conjugated products with disulfide linkage to proteins/peptides for delivery to cells; increases absorption and prolongs blood and tissue retention
03/18/2004US20040054131 Receptor binding amino acid sequences for diagnosis and treatment of tumor and neovascularization disorders
03/18/2004US20040054129 Novel peptides and compositions which modulate apoptosis
03/18/2004US20040053877 Comprises Sendai virus (SeV) vector; analyzed using LacZ reporter gene and insulin-like growth factor; for treatment of neuromusclar disorders
03/18/2004US20040053867 Nucleotide sequences that code for transport proteins; modulation of excitatory amino acids or signal tranduction; detoxification
03/18/2004US20040053866 Tumor suppressor genes and their uses
03/18/2004US20040053864 Prophylaxis and diagnosis of bone disorders such as osteoporosis or paget's disease, by controlling signal transduction, biosynthesis or receptor binding of polypeptide hormones
03/18/2004US20040053863 Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy
03/18/2004US20040053848 Antibodies specific for methylated lysines in histones
03/18/2004US20040053845 Modified peptides as therapeutic agents
03/18/2004US20040053844 Peptide and osteogenetic accelerator
03/18/2004US20040053843 Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
03/18/2004US20040053841 Treating an inflammatory condition in an individual by administering an agent which inhibits the interaction between a Toll-like receptor 2 and a high mobility group B polypeptide
03/18/2004US20040053837 Using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or heterodimer comprising the core domain
03/18/2004US20040053835 Reagents which regulate and bind to human NMDA receptor gene products can play role in preventing, ameliorating, or correcting dysfunctions or diseases including asthma, genito-urinary system disorders
03/18/2004US20040053831 Veterinary immunisation vectors
03/18/2004US20040053829 Polypeptide having preferably antitumoral and/or immunomodulating cytokine properties, which can be activated by processing in vivo comprising a central region with specific biological activity
03/18/2004US20040053828 Partial peptide mimetics and methods
03/18/2004US20040053827 Novel polypeptide human polyadenylation binding protein 20.13 and polynucleotide encoding it
03/18/2004US20040053826 Uses of polypeptides
03/18/2004US20040053824 Nucleic acid and amino acid sequences
03/18/2004US20040053822 Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions
03/18/2004US20040053821 Inhibitors of RGS proteins
03/18/2004US20040053819 Normalizing blood glucose levels by maintaining chronic steady state plasma levels of 60-200 picomoles/liter; subcutaneous injection 1-2 times every 24 hours
03/18/2004US20040053816 Adipocyte culture-cells from fat tissue, liver and kidney from the carp
03/18/2004US20040053812 Methods
03/18/2004US20040053405 Matrix reactor and a method for producing products in said reactor
03/18/2004US20040053397 Comprises sodium glucose transport proteins for treating diabetes and hyperlipidemia; drug screening
03/18/2004US20040053396 Comprises disease detection and treatment (MDDT) polypeptide for diagnosis, treatment, and prevention of developmental, cell proliferative and immunological disorders
03/18/2004US20040053393 Comprises genetically engineered bacteriophage polymerase for detection and treatment of microorganismal infections
03/18/2004US20040053392 Thrombospondin fragments and uses thereof in clinical assays for cancer and generation of antibodies and other binding agents
03/18/2004US20040053391 Renal cell carcinoma-antigen G250-derived peptides that elicit both CD4+ and CD8+ T-cell responses
03/18/2004US20040053389 or Metastatic-tumor Excreted Phosphaturic-Element (MERE) which effects phosphate metabolism ; for diagnosing and treating X-linked rickets, urogenital, kidney and bone disorders
03/18/2004US20040053388 Comprises ubiquitin polypeptide complexes for developing in vivo two-hybrid or interaction trap bioassays for detecting protein partners
03/18/2004US20040053384 Membrane scaffold proteins
03/18/2004US20040053383 Crystals of cytochrome P450 2C9, structures thereof and their use
03/18/2004US20040053372 Comprises prothrombin amino acid sequences for treating thrombosis and blood disorders
03/18/2004US20040053370 Comprises chimeric glucagon-like peptides-1 (GLP-1) for treating obesity and non-insulin dependent diabetes mellitus
03/18/2004US20040053368 Collagen-binding hybrid polypeptide
03/18/2004US20040053367 Lipid-associated molecules
03/18/2004US20040053366 Comprises nucleotide sequences coding leptin chimeric polypeptide for treatment and prevention of weight and cardiovascular disorders
03/18/2004US20040053364 Genetically engineered immunoglobulin receptor for modulating humoral response in transplant patients
03/18/2004US20040053358 Secreted and transmembrane polypeptides and nucleic acids encoding the same
03/18/2004US20040053357 Nucleic acid encoding kv10.1 a voltage-gated potassium channel from human brain
03/18/2004US20040053348 Nucleic acids and corresponding proteins entitled 282P1G3 useful in treatment and detection of cancer
03/18/2004US20040053347 Braf35 protein and brca2/braf35 complex and methods of use
03/18/2004US20040053345 Monitoring and prognosing effectivness of antitumor agents via presence or absence of tumor activator protein menin
03/18/2004US20040053344 Using human leukocyte antigen protein-f to classify and identify cell proliferative disorders
03/18/2004US20040053328 Identifying binding associations and activities of binding partners of cell signaling proteins; signal transduction and gene expression
03/18/2004US20040053313 Activity dependent neurotrophic factor III (ADNF III)
03/18/2004US20040053307 Comprises dual specificity membrane fusion proteins for treatment of transplant, allergenic, autoimmune and immunosuppressive disorders